top of page

LEAP4WA PUBLICATIONS

Swati Gupta;  Donald Grant, Robert Garry, Abdulwasiu Bolagi Tiamiyu, Sandhya Vasan, Stephen Kennedy, Bernice Dahn, James Duworko, Rebecca Grais, Marija Zaric, Patricia Fast; Gaudensia Mutua, Devin Hunt, Kathleen Walker, Shaun Palmer,  Bridgette Connell, Jennifer Lehrman;  LEAP4WA Consortium. Lassa Fever Vaccine Efficacy and Prevention For West Africa (LEAP4WA). 11th EDCTP Forum. November 2023. 

An IAVI-led consortium is advancing a Lassa vaccine candidate based on the recombinant vesicular stomatitis virus (rVSV) platform technology. LEAP4WA will conduct a Phase IIb efficacy trial, evaluating the efficacy of VSV∆G-LASV-GPC for the prevention of laboratory confirmed, symptomatic Lassa fever in a West African LASV-NP seronegative population.
LEAP4WA will also develop state-of-the-art clinical research capacity in West Africa that can be utilized for other Emerging Infectious Diseases in the future.

 

PUBLICATIONS

OTHER RELEVANT PUBLICATIONS

Lawal QO. (2024). Untold Lassa fever story: a physician’s lived experienceLancet Infection 24, e277(2024). doi.org/10.1016/ S1473-3099(24)00148-8.

Penfold S, Adegnika AA, Asogun D, Ayodeji O, Azuogo BN, Fischer II WA et al. (2023). A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme) – Study protocol. PLoS ONE. doi.org/10.1371/journal.pone.0283643

Garry R. (2022). Lassa fever — the road ahead. Nat Rev Microbiol 21, 87–96. doi.org/10.1038/s41579-022-00789-8

Hastie KM, Zandonatti MA, Kleinfelter LM, Heinrich ML, Rowland M, Chandran K, et al. (2017). Structural basis for antibody-mediated neutralization of Lassa Virus. Science 356,923-928(2017). doi.org/10.1126/science.aam7260

Safronetz D, Mire C, Rosenke K, Feldmann F, Haddock E, Geisbert T, Feldmann H. (2015). A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses. PLoS Negl Trop Dis.17;9(4):e0003736. doi: 10.1371/journal.pntd.0003736. PMID: 25884628; PMCID: PMC4401668.

Swati Gupta; Patricia Fast; Jennifer Lehrman; Matt Price; LEAP4WA Consortium. Lassa Fever Vaccine Efficacy and Prevention For West Africa (LEAP4WA). 10th EDCTP Forum. October 2021. 

An IAVI-led consortium is advancing a Lassa vaccine candidate based on the recombinant vesicular stomatitis virus (rVSV) platform technology. The vaccine candidate demonstrated 100% efficacy against LASV in a nonhuman primate challenge study. Furthermore, it uses the same technology as Merck’s ERVEBO® vaccine, which has been shown to be safe and efficacious in preventing Ebola virus disease and is licensed in multiple countries.

bottom of page